A trial, targeted at people living with obesity from Britain to Puerto Rico, is the first head-to-head comparison of the ...

Revolutionary weight management and diabetes medications could prove to be the next frontier in addiction recovery treatment medications.

A new study suggests increasingly popular GLP-1 drugs could help cut opioid and alcohol abuse nearly in half. What doesn’t it ...

The stock of Eli Lilly and Company LLY has declined 1.7% already this week, losing almost $14 billion of its market value.

The drugmaker's financial results are also impressive, spearheaded by tirzepatide, a therapy for diabetes and obesity that is ...

Over the last couple of years, pharmaceutical giant Eli Lilly (NYSE: LLY) has made a splash in the red-hot weight loss space.

Drugs such as Novo Nordisk’s Ozempic can cut drug and alcohol abuse by up to 50%, a study found, adding to mounting evidence ...

The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

“ (Weight loss medications) can help, for sure, but exercise and getting enough protein to make sure you aren’t losing muscle ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.